851 related articles for article (PubMed ID: 31484667)
21. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
[TBL] [Abstract][Full Text] [Related]
22. LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T Cells.
Ngai H; Barragan GA; Tian G; Balzeau JC; Zhang C; Courtney AN; Guo L; Xu X; Wood MS; Drabek JM; Demberg T; Sands CM; Chauvin-Fleurence CN; Di Pierro EJ; Rosen JM; Metelitsa LS
Cancer Immunol Res; 2023 Feb; 11(2):171-183. PubMed ID: 36484736
[TBL] [Abstract][Full Text] [Related]
23. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma.
Singh N; Liu X; Hulitt J; Jiang S; June CH; Grupp SA; Barrett DM; Zhao Y
Cancer Immunol Res; 2014 Nov; 2(11):1059-70. PubMed ID: 25104548
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-15 Enhances Anti-GD2 Antibody-Mediated Cytotoxicity in an Orthotopic PDX Model of Neuroblastoma.
Nguyen R; Moustaki A; Norrie JL; Brown S; Akers WJ; Shirinifard A; Dyer MA
Clin Cancer Res; 2019 Dec; 25(24):7554-7564. PubMed ID: 31455682
[TBL] [Abstract][Full Text] [Related]
25. An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma.
Ma R; Lu T; Li Z; Teng KY; Mansour AG; Yu M; Tian L; Xu B; Ma S; Zhang J; Barr T; Peng Y; Caligiuri MA; Yu J
Cancer Res; 2021 Jul; 81(13):3635-3648. PubMed ID: 34006525
[TBL] [Abstract][Full Text] [Related]
26. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.
Song DG; Ye Q; Poussin M; Harms GM; Figini M; Powell DJ
Blood; 2012 Jan; 119(3):696-706. PubMed ID: 22117050
[TBL] [Abstract][Full Text] [Related]
27. Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.
Yu J; Wu X; Yan J; Yu H; Xu L; Chi Z; Sheng X; Si L; Cui C; Dai J; Ma M; Xu T; Kong Y; Guo J
J Hematol Oncol; 2018 Jan; 11(1):1. PubMed ID: 29298689
[TBL] [Abstract][Full Text] [Related]
28. A High-Avidity T-cell Receptor Redirects Natural Killer T-cell Specificity and Outcompetes the Endogenous Invariant T-cell Receptor.
Landoni E; Smith CC; Fucá G; Chen Y; Sun C; Vincent BG; Metelitsa LS; Dotti G; Savoldo B
Cancer Immunol Res; 2020 Jan; 8(1):57-69. PubMed ID: 31719055
[TBL] [Abstract][Full Text] [Related]
29. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
Seidel D; Shibina A; Siebert N; Wels WS; Reynolds CP; Huebener N; Lode HN
Cancer Immunol Immunother; 2015 May; 64(5):621-34. PubMed ID: 25711293
[TBL] [Abstract][Full Text] [Related]
30. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.
Liu Y; Wu HW; Sheard MA; Sposto R; Somanchi SS; Cooper LJ; Lee DA; Seeger RC
Clin Cancer Res; 2013 Apr; 19(8):2132-43. PubMed ID: 23378384
[TBL] [Abstract][Full Text] [Related]
31. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
32. Engineering genetic devices for in vivo control of therapeutic T cell activity triggered by the dietary molecule resveratrol.
Yang L; Yin J; Wu J; Qiao L; Zhao EM; Cai F; Ye H
Proc Natl Acad Sci U S A; 2021 Aug; 118(34):. PubMed ID: 34404729
[TBL] [Abstract][Full Text] [Related]
33. Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response.
Li X; Daniyan AF; Lopez AV; Purdon TJ; Brentjens RJ
Leukemia; 2021 Feb; 35(2):506-521. PubMed ID: 32447345
[TBL] [Abstract][Full Text] [Related]
34. Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia.
Ataca Atilla P; McKenna MK; Tashiro H; Srinivasan M; Mo F; Watanabe N; Simons BW; McLean Stevens A; Redell MS; Heslop HE; Mamonkin M; Brenner MK; Atilla E
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32938629
[TBL] [Abstract][Full Text] [Related]
35. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.
Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK
Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655
[TBL] [Abstract][Full Text] [Related]
36. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2
Dai Q; Han P; Qi X; Li F; Li M; Fan L; Zhang H; Zhang X; Yang X
Front Immunol; 2020; 11():539654. PubMed ID: 33281809
[TBL] [Abstract][Full Text] [Related]
37. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.
Craddock JA; Lu A; Bear A; Pule M; Brenner MK; Rooney CM; Foster AE
J Immunother; 2010 Oct; 33(8):780-8. PubMed ID: 20842059
[TBL] [Abstract][Full Text] [Related]
38. GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients.
Yu L; Huang L; Lin D; Lai X; Wu L; Liao X; Liu J; Zeng Y; Liang L; Zhang G; Wang B; Wu Z; Tao S; Liu Y; Jiao C; Chang LJ; Yang L
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2643-2652. PubMed ID: 34724115
[TBL] [Abstract][Full Text] [Related]
39. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
[TBL] [Abstract][Full Text] [Related]
40. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
